Status:

COMPLETED

Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients

Lead Sponsor:

University of Brasilia

Conditions:

Localized Cutaneous Leishmaniasis

Eligibility:

All Genders

65+ years

Phase:

PHASE4

Brief Summary

This study was designed to evaluate the effect of low doses of pentavalent antimony (meglumine antimoniate) to treat cutaneous leishmaniasis ulcers in patients older than 65 years. The hypothesis is t...

Eligibility Criteria

Inclusion

  • Age \> 65 years
  • Permanent residence in the endemic area
  • Availability of a caregiver for dependent patients

Exclusion

  • Mucosal disease caused by leishmaniasis
  • Disseminated cutaneous disease
  • Severe cardiac, renal or hepatic disorders
  • Active cancer
  • Active tuberculosis
  • Leprosy
  • HIV positive
  • Total bilirubin \> 1.5mg/dL
  • Urea and creatinin \> 1.5 times the upper normal level
  • Alkaline phosphatase and aminotransferases \> 2.5 times the upper normal level
  • Lipase and amylase \> 1.5 the upper normal level
  • Hemoglobin \< 5 g/dL of

Key Trial Info

Start Date :

August 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2010

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00818818

Start Date

August 1 2008

End Date

April 1 2010

Last Update

October 8 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Health Center Unit of Corte de Pedra

Corte de Pedra, Presidente Tancredo Neves, Bahia State, Brazil, 45416 - 000

Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients | DecenTrialz